SynthesisWorld journal of gastroenterology2014
S-1-based combination therapy vs S-1 monotherapy in advanced gastric cancer: a meta-analysis.
Synthesis in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Management of advanced gastric cancer: An overview of major findings from meta-analysis.Oncotarget · 2016Pooled it
- The efficacy and safety of S-1-based regimens in the first-line treatment of advanced gastric cancer: a systematic review and meta-analysis.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2016Pooled it
- A Meta-analysis Reveals S-1-based Chemotherapy Improves the Survival of Patients With Advanced Gastric Cancer.Medicine · 2015Pooled it
- Case Report: Immune-related colitis complicated byFrontiers in immunology · 2026Article
- Efficacy and Safety of a 3-Weekly TS-1 Adjuvant Regimen in Advanced Gastric Cancer: A Pilot Study.Cancer medicine · 2025Article
- A prognostic nomogram to predict the cancer-specific survival of patients with initially diagnosed metastatic gastric cancer: a validation study in a Chinese cohort.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Article
- Efficacy and safety of SOX chemotherapy with or without surgery in AFP-producing advanced gastric cancer.Oncology letters · 2017Article
- Efficacy and safety comparison of chemotherapies for advanced gastric cancer: A network meta-analysis.Oncotarget · 2017Article
- MiR-154 Functions as a Tumor Suppressor in Glioblastoma by Targeting Wnt5a.Molecular neurobiology · 2017Article
- Identifying therapeutic targets in gastric cancer: the current status and future direction.Acta biochimica et biophysica Sinica · 2016Review
- miR-215 functions as a tumor suppressor and directly targets ZEB2 in human non-small cell lung cancer.Oncology letters · 2015Article
- Decreased miR-154 expression and its clinical significance in human colorectal cancer.World journal of surgical oncology · 2015Article
- miR-32 functions as a tumor suppressor and directly targets SOX9 in human non-small cell lung cancer.OncoTargets and therapy · 2015Article
- MiR-32 functions as a tumor suppressor and directly targets EZH2 in human oral squamous cell carcinoma.Medical science monitor : international medical journal of experimental and clinical research · 2014Article
- MiR-206 functions as a tumor suppressor and directly targets K-Ras in human oral squamous cell carcinoma.OncoTargets and therapy · 2014Article
- MiR-32 Inhibits Proliferation and Metastasis by Targeting EZH2 in Glioma.Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo assess the efficacy and safety of combination therapy based on S-1, a novel oral fluoropyrimidine, vs S-1 monotherapy in advanced gastric cancer (AGC).
methodsWe searched PubMed, EMBASE and the Cochrane Library for eligible studies published before March 2013. Our analysis identified four randomized controlled trials involving 790 participants with AGC. The outcome measures were overall survival (OS), progression-free survival (PFS), overall response rate (ORR) and grade 3-4 adverse events.
resultsMeta-analysis showed that S-1-based combination therapy significantly improved OS (HR = 0.77, 95%CI: 0.66-0.91, P = 0.002), PFS (HR = 0.58, 95%CI: 0.46-0.72, P = 0.000) and ORR (OR = 2.23, 95%CI: 1.54-3.21, P = 0.000). Sensitivity analysis further confirmed this association. Lower incidence of grade 3-4 leucopenia (OR = 4.06, 95%CI: 2.11-7.81), neutropenia (OR = 3.94, 95%CI: 2.1-7.81) and diarrhea (OR = 2.41, 95%CI: 1.31-4.44) was observed in patients with S-1 monotherapy.
conclusionS-1-based combination therapy is superior to S-1 monotherapy in terms of OS, PFS and ORR. S-1 monotherapy is associated with less toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.